Related Experiment Video
Updated: Apr 5, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
14.0K
A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
Li Wang1,2, Yixuan Gong3, Uma Chippada-Venkata3
1Icahn Institute for Genomics and Multiscale Biology, New York, NY, 10029, USA.
BMC Medicine
|August 23, 2015
Summary
A new four-gene model from whole blood mRNA predicts survival in castration-resistant prostate cancer (CRPC). This robust biomarker, linked to immune cell gene expression, offers superior prognostic power compared to existing models.
Area of Science:
- Genomics
- Oncology
- Biomarker Discovery
Background:
- Castration-resistant prostate cancer (CRPC) exhibits significant survival variability.
- Existing mRNA expression biomarkers for CRPC survival lack overlapping genes and unknown relationships.
- A robust biomarker model is needed to capture biological drivers of CRPC lethality.
Purpose of the Study:
- To develop a novel, robust biomarker model for CRPC survival prediction.
- To integrate genomic approaches for understanding cancer progression.
- To identify underlying biological processes driving CRPC lethality.
Main Methods:
- Utilized three independent CRPC patient cohorts.
- Employed an integrative genomic approach to analyze gene expression.
- Developed and validated a novel four-gene prognostic model.
Main Results:
- Identified myeloid- and lymphoid-specific gene expression patterns in whole blood mRNA.
- Discovered that upregulated genes in poor-survival patients were myeloid-specific, downregulated genes were lymphocyte-specific.
- The novel four-gene model demonstrated independent prognostic power and outperformed existing models in CRPC patients.
Conclusions:
- Whole blood mRNA profiling offers clinically relevant prognostic information for CRPC.
- Integrative genomics revealed immune cell-related gene expression changes predicting CRPC survival.
- Further validation in larger cohorts is warranted to quantify prognostic improvement.
